Literature DB >> 8428000

Interleukin-3 expression by activated T cells involves an inducible, T-cell-specific factor and an octamer binding protein.

K Davies1, E C TePas, D G Nathan, B Mathey-Prevot.   

Abstract

Interleukin-3 (IL-3) is exclusively expressed by activated T and natural killer cells, a function that is tightly controlled both in a lineage-specific and in a stimulation-dependent manner. We have investigated the protein binding characteristics and functional importance of the ACT-1-activating region of the IL-3 promoter. This region binds an inducible, T-cell-specific factor over its 5' end, a site that is necessary for the expression of IL-3 in the absence of other upstream elements. Over its 3' end, it binds a factor that is ubiquitously and constitutively expressed. This factor is Oct-1 or an immunologically related octamer-binding protein, and it plays a role in coordinating the activity of several regulatory elements. These characteristics make the ACT-1 site analogous to the activating ARRE-1 site in the IL-2 promoter. Furthermore, and despite a lack of sequence homology, the promoters of IL-3 and IL-2 share an organizational pattern of regulatory elements that is likely to be important for the T-cell-specific expression of these genes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8428000

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  3 in total

1.  Molecular cloning of a novel human cDNA encoding a zinc finger protein that binds to the interleukin-3 promoter.

Authors:  N Koyano-Nakagawa; J Nishida; D Baldwin; K Arai; T Yokota
Journal:  Mol Cell Biol       Date:  1994-08       Impact factor: 4.272

2.  Molecular cloning and characterization of NF-IL3A, a transcriptional activator of the human interleukin-3 promoter.

Authors:  W Zhang; J Zhang; M Kornuc; K Kwan; R Frank; S D Nimer
Journal:  Mol Cell Biol       Date:  1995-11       Impact factor: 4.272

3.  Molecular regulation of the human IL-3 gene: inducible T cell-restricted expression requires intact AP-1 and Elf-1 nuclear protein binding sites.

Authors:  L R Gottschalk; D M Giannola; S G Emerson
Journal:  J Exp Med       Date:  1993-11-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.